Featured Research

from universities, journals, and other organizations

New biodegradable compound facilitates bone regeneration in cases of substantial loss

Date:
July 30, 2010
Source:
Basque Research
Summary:
Bones have a capacity to regenerate themselves after suffering partial damage. However, it is really quite another thing when a serious break or tumor lesion occurs and the loss of tissue is substantial. Today these cases are treated with various kinds of grafts, but they have a number of disadvantages, such as rejection, contamination or limitations on donors. Researchers are developing a biodegradable porous support which will temporarily substitute for the damaged bone.

Bones have a capacity to regenerate themselves after suffering partial damage. However, it is really quite another thing when a serious break or tumour lesion occurs and the loss of tissue is substantial. Today these cases are treated with various kinds of grafts, but they have a number of disadvantages, such as rejection, contamination or limitations on donors.

As a consequence, the current tendency in bone tissue engineering is developing materials that temporarily substitute for the bone while inducing its regeneration in such a way that this, temporary material, disappears as the bone recovers its space. Ms Beatriz Olalde, researcher at the Health Unit of Tecnalia, is working on the creation of one of these compounds. With the results obtained to date, she has presented her PhD thesis at the University of Basque Country (UPV/EHU), entitled, Development of a new porous, biodegradable nanocompound support for the regeneration of bone tissue.

The porous support or foam, developed by Ms Olalde and defended in her thesis, is totally new. The aim was to manufacture a biodegradable porous support which, while temporarily substituting for the damaged bone, would be capable of inducing a process of bone regeneration. With this in mind, a compound was developed which is capable of interacting -- both chemically and electrically -- with the bone cells or the adjoining bone tissue, thus accelerating bone recovery.

Polylactic acid, hydroxyapatite and carbon nanotubes

The basis of the composition of the porous support presented in the thesis is a polymer: polylactic acid, a material widely used in medicine and which, given its biodegradable properties, disappears as the bone grows. To this the researcher added a bioceramic -- hydroxyapatite. Polymers have difficulties in attracting cells and so the function of hydroxyapatite, which provides calcium, is facilitating this integration of the support into the surrounding bone cells.

Finally, the compound also has carbon nanotubes. These enhance the mechanical properties of the polymers, which are limited in this aspect and would otherwise break up given bone resistance. Moreover, it is the carbon nanotubes that provide the electrical character to the porous support, as both the polylactic acid and the hydroxyapatite are insulating materials. In this manner, an electric field can be applied in such a way that the bone cells are directed to the porous support and the regeneration process is accelerated.

According to Ms Olalde in her thesis, the trials undertaken with the new porous support, involving both in vitro and in vivo experiments, gave satisfactory results. The foam proved to have optimum mechanical properties for supporting the bone well and, moreover, it does not break up once implanted. What is more, with the initial in vivo results, obtained 3 weeks alter being implanted in the porous support, bone growth was already observed. Also, after 16 weeks, this new bone showed mechanical, histomorphometric and densitometric properties similar to those of intact or healthy bone tissue.


Story Source:

The above story is based on materials provided by Basque Research. Note: Materials may be edited for content and length.


Cite This Page:

Basque Research. "New biodegradable compound facilitates bone regeneration in cases of substantial loss." ScienceDaily. ScienceDaily, 30 July 2010. <www.sciencedaily.com/releases/2010/07/100730091015.htm>.
Basque Research. (2010, July 30). New biodegradable compound facilitates bone regeneration in cases of substantial loss. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100730091015.htm
Basque Research. "New biodegradable compound facilitates bone regeneration in cases of substantial loss." ScienceDaily. www.sciencedaily.com/releases/2010/07/100730091015.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins